Simplifying Antiretroviral Therapy: Two-Drug Regimens and Long-Acting Treatment

Presenters

Joseph J. Eron, Jr, MD
The University of North Carolina at Chapel Hill

Start

January 21, 2020 - 10:00 AM

End

January 21, 2020 - 11:15 AM

Overview

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide continuing medical education (CME) effort for physicians on the evolving challenges of managing HIV disease. This webinar will discuss the goals of antiretroviral therapy in people living with HIV (PLWH) who are currently in care and are successfully treated. Further, this webinar will review reasons for therapy simplification and clinical considerations to take into account when contemplating therapy switch. Data on 2-drug regimens for virally suppressed patients will be reviewed, including the recent data on combination long-acting therapy.

Learning Objectives

At the end of the presentation, participants will be able to:

  • Describe clinical information needed when contemplating HIV-regimen simplification in PLWH who are virally suppressed on therapy
  • Understand the potential advantages and disadvantages of two-drug therapy in PLWH who are considering switching therapy
  • Summarize the results of the Phase III studies of long-acting antiretroviral therapy

Registration

Who Should Attend

This advanced webinar is designed for physicians who are actively involved in HIV and STI care and research. It is also relevant for registered nurses, PharmDs, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Monday, January 21, 2020, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

This activity is eligible for ANCC credit; see the final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo This activity is eligible for ACPE credit; see the final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS
Gilead Sciences, Inc
ViiV Healthcare

GOLD SUPPORTER
Merck & Co, Inc

SILVER SUPPORTER
Cepheid

Additional support has been provided by
Hologic

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.